Marufa Akter ruled out of New Zealand tour; board says no rush on comeback

Dhaka: Bangladesh women's team fast bowler Marufa Akter will not play in the upcoming white-ball series against New Zealand. A senior official from the Bangladesh Cricket Board (BCB) women's wing has confirmed that Marufa is unavailable for the tour. The team will depart Dhaka for New Zealand on December 4, where three ODIs and three T20Is are scheduled. Marufa has been struggling with a foot injury for some time. Reports indicate bone erosion at the base of her fifth metatarsal. Under the treatment plan, she has been advised to wear an Aircast brace and rest for approximately four weeks. She is expected to be able to walk around in the first week of December, which aligns with the four-week rest cycle. At the time the team departs Dhaka, she will barely be in a position to walk. According to the BCB official, there will be no rush over Marufa's return. "Marufa is unavailable for the New Zealand tour. We want to give her enough time so that the injury does not recur," the official said. The official added that the player and the medical team are monitoring her recovery together, but no fixed date for her return has been set. Marufa was seen battling this injury during the Australia tour. According to reports, she was given an injection before the tour to relieve the pain, but it did not have the expected effect. She subsequently did not play the final match of the Australia tour. The pain is said to have resurfaced, prompting the medical team to choose rest and stabilization. The development is a concern for Bangladesh's pace bowling plans. Marufa is regarded as one of the team's leading fast bowlers, although no detailed statistics are provided in this report to support the claim. New Zealand conditions are generally considered helpful to fast bowlers, and her absence could affect the team's bowling balance. Several important pieces of information are missing from this report. It is not clear whether Marufa was originally part of the squad selected for the New Zealand tour. If she was in the squad, there is no mention of who was included in her place. Likewise, the dates of the series matches have not been given, making it difficult to estimate when she might be able to return. There are also differing claims about the events during the Australia tour. It is not stated what type of injection was given or who administered it. No official statement has come from the medical team. The only source cited is an unnamed official described as a "top BCB official working closely with the board's women's unit." According to general sports medicine knowledge, the base of the fifth metatarsal is considered a watershed area for blood supply, and injuries there take longer to heal. This is why the medical team is emphasizing rest and reduced loading. However, the claim of "four weeks of bed rest" may be considered stricter than the usual treatment for this type of injury; typically, non-weight-bearing is advised rather than strict bed rest. The biggest challenge for the team management is that no timeline for return has been set. The official's statement suggests that no pressure will be put on Marufa for a quick comeback. This approach may be right for the player's long-term career, but it leaves uncertainty for team selection. To assess Marufa's bowling, it will be necessary to put her recent performance statistics on the table. This report does not state how many overs she bowled or how many wickets she took in the last series. Likewise, there is no mention of the depth of Bangladesh's fast bowling bench strength. The significance of the New Zealand tour also depends on whether this series is part of a particular tournament. This report makes no mention of it. If the series is part of preparations for an ICC tournament, the impact of Marufa's absence would be different. No official medical report or team announcement has been made public by the board so far. As such, several important aspects of this news remain unresolved. In particular, the question remains whether Marufa might need surgery. Bone erosion, the injection not working, and the use of a brace are signals that warrant further monitoring. The unnamed official is identified as a "top BCB official working closely with the board's women's unit," suggesting the information came from an internal source. But such a source cannot be independently verified. Therefore, this news should be seen as a report rather than treated as final truth. Bangladeshi media may also comment on this news. If local reporters confirm it, the credibility of the information will increase. For now, it is unclear when the board will issue an official statement. In the meantime, the team management will have to work on its bowling strategy. The New Zealand tour includes three ODIs and three T20Is, and the role of fast bowlers differs between the two formats. With Marufa absent, who will take responsibility with the new ball is an important question. It also remains to be seen what the board's strategy is in Marufa's case. If she is out for a long time, it could affect her career. Injuries are common among fast bowlers, but a return is possible with the right management. In the end, the gist of this news is that Marufa Akter is out of the New Zealand tour, there is no fixed date for her return, and it is not yet clear who will replace her. An official board statement on these points is awaited.